Comment on “Therapeutic Effects and Biomarkers in Sublingual Immunotherapy : A Review”

Abstract EN

Numerous sublingual immunotherapy studies have shown efficacy using a wide variety of dosing regimens.

Despite a few grade III and one anaphylactic reaction due to a patient over-dose, there have been no fatal reactions resulting from sublingual immunotherapy treatment.

Although safer than SCIT, SLIT is still immunotherapy.

Special consideration should be given to what will ensure the highest level of safety for the patient given his or her history, exam and allergy test results.

Dosing levels for sublingual immunotherapy should be based on what is therapeutically effective for each individual patient and adjusted accordingly throughout the treatment course.